TABLE 2.
Characteristics of IFI patients.
| Characteristics | Overall (n = 24) | Survival (n = 3) | Non-survival (n = 21) | P-value |
| Gender (%) | 0.285 | |||
| Male | 18 (75.00%) | 3 (100.00%) | 15 (71.43%) | |
| Female | 6 (25.00%) | 0 (0.00%) | 6 (28.57%) | |
| Age category, year (%) | 0.089 | |||
| <=48 | 13 (54.17%) | 3 (100.00%) | 10 (47.62%) | |
| >48 | 11 (45.83%) | 0 (0.00%) | 11 (52.38%) | |
| Age | 48.0 (38.8, 61.5) | 37.0 (34.5, 39.0) | 49.0 (41.0, 66.0) | 0.054 |
| IFI diagnosis time days continuous, day | 17.50 (13.50, 23.00) | 25.00 (17.00, 57.00) | 17.00 (14.00, 21.00) | 0.037 |
| Treatment time continuous, day | 5.00 (2.00, 8.50) | 16.00 (10.50, 29.00) | 5.00 (1.75, 5.50) | 0.012 |
| Length of hospitalization continuous, day | 21.50 (16.75, 28.50) | 41.00 (27.50, 86.00) | 21.00 (17.00, 26.00) | 0.004 |
| HBsAg category (%) | 0.118 | |||
| <=2700 | 10 (41.67%) | 0 (0.00%) | 10 (47.62%) | |
| >=2700 | 14 (58.33%) | 3 (100.00%) | 11 (52.38%) | |
| HBeAg status (%) | 0.19 | |||
| Negative | 8 (33.33%) | 0 (0.00%) | 8 (38.10%) | |
| Positive | 16 (66.67%) | 3 (100.00%) | 13 (61.90%) | |
| HBV DNA statue (%) | 0.008 | |||
| Negative | 1 (4.35%) | 1 (33.33%) | 0 (0.00%) | |
| Positive | 22 (95.65%) | 2 (66.67%) | 20 (100.00%) | |
| Neutrophilic granulocyte percentage category (%) | 0.132 | |||
| 40–75 | 1 (4.17%) | 0 (0.00%) | 1 (4.76%) | |
| <=40 | 11 (45.83%) | 3 (100.00%) | 8 (38.10%) | |
| >=75 | 12 (50.00%) | 0 (0.00%) | 12 (57.14%) | |
| Neutrophilic granulocyte category, 10^9/l | 0.026 | |||
| 1.8–6.3 | 1 (4.17%) | 1 (33.33%) | 0 (0.00%) | |
| <=1.8 | 11 (45.83%) | 1 (33.33%) | 10 (47.62%) | |
| >=6.3 | 12 (50.00%) | 1 (33.33%) | 11 (52.38%) | |
| Total bilirubin, umol/l | 286.80 (235.72, 402.90) | 202.20 (190.55, 235.25) | 305.50 (251.40, 445.80) | 0.164 |
| Globulin, g/l | 24.50 (20.43, 30.95) | 30.50 (28.15, 34.30) | 22.70 (19.30, 29.10) | 0.188 |
| Alanine aminotransferase category, U/l | 0.091 | |||
| <=50 | 3 (12.50%) | 0 (0.00%) | 3 (14.29%) | |
| >50 | 10 (41.67%) | 3 (100.00%) | 7 (33.33%) | |
| 2 | 11 (45.83%) | 0 (0.00%) | 11 (52.38%) | |
| Procalcitonin category, ng/ml | 0.335 | |||
| <=0.1 | 3 (15.00%) | 1 (33.33%) | 2 (11.76%) | |
| >0.1 | 17 (85.00%) | 2 (66.67%) | 15 (88.24%) | |
| Use of antibiotics (%) | 0.699 | |||
| No | 1 (4.17%) | 0 (0.00%) | 1 (4.76%) | |
| Yes | 23 (95.83%) | 3 (100.00%) | 20 (95.24%) | |
| Use of glucocorticoids (%) | 0.342 | |||
| No | 5 (20.83%) | 0 (0.00%) | 5 (23.81%) | |
| Yes | 19 (79.17%) | 3 (100.00%) | 16 (76.19%) | |
| Creatinine, μmol/l | 55.00 (41.25, 66.50) | 37.00 (35.00, 46.00) | 55.00 (46.00, 68.00) | 0.477 |
| Hemoptysis (%) | 0.007 | |||
| No | 23 (95.83%) | 2 (66.67%) | 21 (100.00%) | |
| Yes | 1 (4.17%) | 1 (33.33%) | 0 (0.00%) | |
| Dyspnea (%) | 0.285 | |||
| No | 18 (75.00%) | 3 (100.00%) | 15 (71.43%) | |
| Yes | 6 (25.00%) | 0 (0.00%) | 6 (28.57%) | |
| Pleuritic chest pain (%) | 0.007 | |||
| No | 23 (95.83%) | 2 (66.67%) | 21 (100.00%) | |
| Yes | 1 (4.17%) | 1 (33.33%) | 0 (0.00%) |
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; IFI, invasive fungal infection; HBV DNA, hepatitis B virus deoxyribonucleic acid.